Teitur Hosts First Scientific Advisory Board Meeting for Lead Program TT-P34

Teitur Trophics has recently hosted its first Scientific Advisory Board (SAB) Meeting. This is an important milestone in the development of Teitur's lead program, TT-P34. We brought together a distinguished panel of internationally recognized Parkinson’s disease and translational medicine experts:

‍

Dr. Günter Höglinger (LMU Munich)

Dr. Margherita Fabbri (CHU Toulouse)

Dr. Nicola Pavese (NIHR Newcastle)

Dr. Joachim Scholpp (Industry Executive & Advisor)

‍

During the meeting, our advisors shared invaluable insights, experience, and strategic guidance to help shape the next steps in TT-P34’s development. The discussion focused on refining the Phase II planning and strategy for TT-P34, a novel peptide-based therapeutic targeting mitochondrial and lysosomal dysfunction. Their contributions are critical to our efforts to optimize our development strategy and move this promising therapy closer to the first patient trial.

‍

This first SAB marks an important step forward in Teitur’s mission to develop transformative treatments for neurodegenerative diseases.

‍

‍